SEC Filing Analysis: EXACT SCIENCES CORP (EXAS)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An executive at Exact Sciences conducted a small, pre-planned sale of common stock valued at approximately $200,000.
• Market Impact: The transaction is immaterial relative to the company's market capitalization and is unlikely to influence the stock price.

Company Information

Field	Value
Company	EXACT SCIENCES CORP
Ticker Symbol	EXAS
CIK	0001124140
Industry	SERVICES-MEDICAL LABORATORIES

Insider Information

Field	Value
Name	Baranick Brian
CIK	0001941313
Title/Position	EVP, GM, Precision Oncology
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-04
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	2,858
Price Per Share	$70.08
Total Value	$200,288.64
Shares Owned After	22,368 (Directly)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$200,288.64
% of Market Cap	0.0015%
Shares Transacted	2,858
% of Shares Outstanding	0.0015%
Post-Transaction Ownership	23,038 shares (0.012% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $200k transaction is negligible for a company with a market capitalization of $13.19 billion.
• Ownership Concentration: The insider's total holdings of 23,038 shares (including indirect) represent a very small fraction (0.012%) of the total shares outstanding.
• Transaction Significance: The sale is quantitatively insignificant, representing less than 0.01% of both market cap and shares outstanding. It constitutes a small portion of the insider's reported direct and indirect holdings.

Additional Context

Special Circumstances

• The sale was executed pursuant to a Rule 10b5-1 trading plan established on May 13, 2024. This indicates the transaction was pre-scheduled and not based on recent material non-public information.